Xeris Biopharma Holdings (LTS:0A8E) 3-Year Revenue Growth Rate : 35.50% (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Xeris Biopharma Holdings 3-Year Revenue Growth Rate?

Xeris Biopharma Holdings's Revenue per Share for the three months ended in Mar. 2024 was $0.29.

During the past 12 months, Xeris Biopharma Holdings's average Revenue per Share Growth Rate was 38.70% per year. During the past 3 years, the average Revenue per Share Growth Rate was 35.50% per year. During the past 5 years, the average Revenue per Share Growth Rate was 55.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 8 years, the highest 3-Year average Revenue per Share Growth Rate of Xeris Biopharma Holdings was 98.50% per year. The lowest was -40.60% per year. And the median was 35.50% per year.

Competitive Comparison of Xeris Biopharma Holdings's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Xeris Biopharma Holdings's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Xeris Biopharma Holdings's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xeris Biopharma Holdings's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Xeris Biopharma Holdings's 3-Year Revenue Growth Rate falls into.

Xeris Biopharma Holdings 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Xeris Biopharma Holdings (LTS:0A8E) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Xeris Biopharma Holdings 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Xeris Biopharma Holdings's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Xeris Biopharma Holdings (LTS:0A8E) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xeris Biopharma Holdings Inc (LTS:0A8E) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

XERS:USA 2B30:Germany

Address

180 North LaSalle Street, Suite 1600, Chicago, IL, USA, 60601

Website

https://www.xerispharma.com

Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome.

Xeris Biopharma Holdings (LTS:0A8E) Headlines

No Headlines